In August 2006, the UK Medicines and Healthcare products Regulatory Authority granted authorisation to start first-in-man studies with AR-709. Results were published on 29 March 2007. These showed that AR-709 achieves high concentrations in the key compartments of the lungs where pathogens can reside and replicate. Moreover, the results of the studies showed that AR-709 exhibited a large volume of distribution and a long half life in man. Three possible routes of administration are under investigation: intravenous, oral and targeted delivery. The latter could have the added benefit of avoiding unnecessary systemic exposure.
Additional studies are ongoing in order to initiate Phase I studies in humans.
AR-2474 originates from Arpidas own drug discovery efforts. It is an antibiotic with a novel mechanism of action that has demonstrated, both in vitro and in vivo, to be highly effective in eradicating multi-drug resistant bacteria known to cause topical infections. AR-2474 is being developed as a topical therapy for different applications, including infections of the skin and eye as well as nasal carriage of MRSA.
In March, results from preclinical studies were published, showing AR-2474 to be at least as efficacious as the gold standard mupirocin (Batroban ) in two distinct preclinical models of MRSA infection of the skin and MRSA nasal carriage.
Additional preclinical studies are currently ongoing.
Early-stage research programmes
Arpida has a number of programmes at earlier research stages. Efforts are focussed on a number of selected targets. Crystallisation and co-crystallisation of these target proteins and inhibitory molecules could open up new avenues for rational drug design.
In February 2007 Arpida announced an important focusing of the research
organisation, concentrating operations in the headquarters in Reinach,
Switzerland. This strategic re-
Copyright©2007 PR Newswire.
All rights reserved